Platelet concentration systems are designed for safe and rapid preparation of platelet rich plasma at the point-of-care from a small amount of patient’s blood sample.
Platelet-rich plasma is a non-surgical alternative to cure areas such as orthopedics, sports medicine, dentistry, ENT, neurosurgery, ophthalmology, urology, and wound healing as well as cosmetic, cardiothoracic, and maxillofacial surgery.
The global platelet concentration systems market is estimated to be valued at US$ 286.9 million in 2020 and is expected to exhibit a CAGR of 21.2% during the forecast period (2020-2027).
Figure 1. Global Platelet Concentration Systems Market Share (%) Analysis, By Technology, 2020
Increasing technological advancements in platelet concentration systems is expected to drive the global platelet concentration systems market growth
Introduction of technologically advanced platelet concentration systems for the preparation of autologous blood concentrate is expected to increase demand for platelet concentration systems in the near future.
For instance, PEAK PRP System of DePuy Synthes prepares highly concentrated 3 ml of PRP from 27 ml of whole blood in two and half minutes.
Moreover, in 2018, APEX Biologix launched a new XCELL PRP system. The XCELL PRP system has a specialized concentrating device that helps to shorten the total processing time and reduce human error compared to other systems.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2019 | Market Size in 2020: | US$ 286.99 Mn |
| Historical Data for: | 2017 to 2019 | Forecast Period: | 2020 to 2027 |
| Forecast Period 2020 to 2027 CAGR: | 21.2% | 2027 Value Projection: | US$ 1110.45 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Anthrax Inc., Stryker Corporation, Johnson & Johnson’s, Zimmer Biomet Holdings Inc., Terumo Corporation, Arteriocyte Medical Systems, Inc., Exactech Inc., Harvest Technologies Corp., and Nuo Therapeutics, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Global Platelet Concentration Systems Market- Restraints
Lack of standardization in preparation and dosage of autologous blood concentrate and platelet-separation techniques is a major factor hindering growth of the market.
Global Platelet Concentration Systems Market – Regional Analysis
North America accounted for the largest share in the platelet concentration systems market in 2019 due to increasing cosmetic surgery, orthopedic surgeries, and sports injuries. For instance, according to the American society of plastic surgeons, in 2015, around 15.9 million cosmetic procedures were done in the U.S.
Furthermore, Europe is expected to observe the fastest growth during the forecast period, owing to increasing geriatric population and high adoption of knee osteoarthritis treatment by age group. For instance, according to the study ‘Osteoarthritis in Europe: Impact on health status, work productivity and use of pharmacotherapies in five European countries’ that examined the impact of peripheral joint osteoarthritis across five European countries, U.K. (43.6%), France, (25.6%), Germany, (15.2%), Spain, (8.4%), and Italy (7.1%) recorded high prevalence of peripheral joint osteoarthritis.
Figure 2. Global Platelet Concentration Systems Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Global Platelet Concentration Systems Market- Competitive Landscape
Key players operating in the global platelet concentration systems market include Anthrax Inc., Stryker Corporation, Johnson & Johnson’s, Zimmer Biomet Holdings Inc., Terumo Corporation, Arteriocyte Medical Systems, Inc., Exactech Inc., Harvest Technologies Corp., and Nuo Therapeutics, Inc.
Platelet rich plasma (PRP) is a portion of the plasma fraction of analogous blood, which contains platelet concentration more than standard concentration. Platelets contain bio proteins that help in healing, tissue regeneration and blood loss. Platelet rich plasma is used for the treatment of injured tendons, muscle, joints, and ligaments.
Market Dynamics
Increasing healthcare facilities for geriatric population and sports injuries has boosted growth of the market. Increasing concern of the young population about aesthetic appeal has propelled the market growth due to applications of PRP in cosmetic surgery. For instance, according to the American Society of Plastic Surgeons (ASPS) reports, platelet-rich plasma (PRP) treatment was estimated to increase by 12% from around 113,356 procedures in 2017 to around 127,394 procedures in 2018.
Furthermore, increasing number of orthopedic surgeries and sports injuries, and new product approvals are expected to propel growth of the market during the forecast period. For instance, in 2018, according to the Arthritis Foundation reports, 54 million adults and approximately 300,000 babies and children suffered from arthritis in the U.S.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients